Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
cystic fibrosis
Biotech
Enterprise posts CF win, succeeding where Big Pharma stumbled
The phase 2 trial hit its primary endpoint, furthering the biotech’s pursuit of a target that companies including Vertex have worked on previously.
Nick Paul Taylor
May 12, 2026 4:00am
Blackstone Invests $250M in Anagram to reduce CF pill burden
May 7, 2026 10:36am
Vertex drops Moderna-partnered inhaled CF candidate
May 4, 2026 5:48pm
Boehringer axes gene therapy after seeing cystic fibrosis data
Feb 17, 2026 1:12pm
Arcturus' stock halves on cystic fibrosis readout
Oct 22, 2025 1:01pm
Arcturus doubles down on mRNA, axes several early-stage assets
May 13, 2025 1:32pm
